FOR IMMEDIATE RELEASE – July 11, 2022
CPR Therapeutics Inc. (CPR-T), a start-up medical device company, announced today that it has received a National Science Foundation (NSF) Small Business Technology Transfer (STTR) Phase I award for its project “A MULTIMODAL INTEGRATED SYSTEM FOR IMPROVED CARDIOPULMONARY RESUSCITATION” in the amount of $256K. The award is for a collaboration with The Johns Hopkins Hospital in Baltimore, MD.
CPR Therapeutics is developing multimodal cardiopulmonary resuscitation (CPR), a more effective form of automated mechanical CPR. Sudden cardiac arrest is the leading cause of death in western countries and there are currently no devices more effective than manual CPR. Intact survival after sudden cardiac arrest is below 10% in most communities.
Norman Paradis MD, CPR Therapeutics Founder and CEO said “We are excited to have received this validation of our efforts from one of the most prestigious scientific organizations in the world. The NSF has an extraordinary record of identifying and supporting innovations that eventually reach the bedside and improve patient outcomes.”
Henry Halperin MD, the company’s Chief Scientific Officer and a Professor of Cardiology at Johns Hopkins said “this support will significantly advance our ongoing preclinical development of multimodal CPR. In particular, it will allow us to focus on optimizing the synergies between the multiple pump mechanisms and refine the synchronization with electrical countershock.”
Studies supported by the award will begin immediately and will accelerate the company’s plan to commercialize an in-hospital version of its Vest-CPR System™.
CPR Therapeutics Inc.
CPR Therapeutics Inc. is a medical device start-up company developing the first advanced technology automated CPR system that integrates and synchronizes multiple technological innovations into a single system that can be easily applied under emergency conditions. The Company believes that this technology will, for the first time, demonstrate clinically significant improvements in intact survival after sudden death. The largest killer in Western Countries. Info@CPRTherapeutics.com
DISCLAIMER: The information provided pertaining to CPR Therapeutics Inc. (“CPR-T” or the “Company”), its business assets, strategy and operations is for general informational purposes only and is not a formal offer to sell or a solicitation of an offer to buy any securities, options, futures, or other derivatives related to securities in any jurisdiction and its content is not prescribed by securities laws. Information contained in this presentation should not be relied upon as advice to buy or sell or hold such securities or as an offer to sell such securities. This presentation does not take into account nor does it provide any tax, legal or investment advice or opinion regarding the specific investment objectives or financial situation of any person. While the information in this presentation is believed to be accurate and reliable, CPR-T and its agents, advisors, directors, officers, employees and shareholders make no representation or warranties, expressed or implied, as to the accuracy of such information and CPR-T expressly disclaims any and all liability that may be based on such information or errors or omissions thereof. CPR-T reserves the right to amend or replace the information contained herein, in part or entirely, at any time, and undertakes no obligation to provide the recipient with access to the amended information or to notify the recipient thereof.